The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures.

Journal of Thrombosis and Thrombolysis
Soumaya El RoubyJawed Fareed

Abstract

Enoxaparin is increasingly used for the anticoagulation of patients undergoing percutaneous coronary intervention (PCI). Several reports have suggested the utility of using point of care tests in monitoring the anticoagulation levels of enoxaparin in patients undergoing PCI. The objective of this study was to evaluate a new point-of-care test (POCT) HEMONOX in monitoring the anticoagulant effect of enoxaparin in non citrated fresh whole blood samples from patients undergoing elective PCI procedure. Following IRB approval, blood samples were obtained from fifty-four patients who received two sequential intravenous doses of enoxaparin; 0.1 mg/kg followed 5 min later by 0.4 mg/kg for a total of 0.5 mg/kg. Blood was drawn at baseline and at 5, 10, 30 and 60 min post first bolus for evaluation in the clot-based POCT HEMONOX, ACT and aPTT and the chromogenic anti-Xa activity assay. HEMONOX clotting time (CT) at baseline was 62.6 +/- 6.2 secs, (n = 32) in healthy donors and statistically higher in PCI patients (71.6 +/- 9.1 secs, p = 0.0001). The peak HEMONOX response that was always achieved at 10 min post bolus was >100 secs in all 54 patients, of these 83% yielded CT >150 secs (range: 150-466). There was no detectable anti-Xa activ...Continue Reading

References

Jun 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·D A HoppensteadtE W Bermes
Dec 22, 1999·The American Journal of Cardiology·M M RabahC L Grines
Oct 3, 2002·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Muhammad Shakil AslamJeffrey B Lakier
Dec 12, 2002·Journal of the American College of Cardiology·Rémi ChoussatDaniel Thomas
Jan 15, 2003·JAMA : the Journal of the American Medical Association·Graham C WongElliott M Antman
Jan 23, 2003·Circulation·Shaun G GoodmanUNKNOWN Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators
Feb 7, 2003·Journal of the American College of Cardiology·Deepak L BhattUNKNOWN Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study
Feb 11, 2003·Journal of the American College of Cardiology·Jonathan D MarmurMerwin F Richard
Mar 20, 2003·Journal of the American College of Cardiology·Marc Cohen
Sep 19, 2003·Journal of the American College of Cardiology·David J MoliternoUNKNOWN ELECT Investigators
Dec 30, 2003·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Mark LawrenceGregory J Dehmer
Feb 3, 2004·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Jack L MartinFrederique Bigonzi
Feb 26, 2004·The Annals of Pharmacotherapy·Robert C GosselinJohn T Owings
Mar 26, 2004·Thrombosis Research·Jacqueline SawDavid J Moliterno

❮ Previous
Next ❯

Citations

Jan 8, 2011·Journal of Thrombosis and Thrombolysis·Mario A InchiosaIris Navarro
Dec 25, 2013·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Ruben PauwelsAnnemieke Dhondt
Sep 17, 2011·AJNR. American Journal of Neuroradiology·H M HusseinA I Qureshi
Feb 11, 2014·Expert Review of Cardiovascular Therapy·Shaun BhattyIon S Jovin
Aug 23, 2012·Best Practice & Research. Clinical Anaesthesiology·Klaus GörlingerDaniel Dirkmann
Feb 23, 2010·Journal of the American College of Cardiology·Johanne SilvainGilles Montalescot

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.